Despite biosimilars generating $467 billion in healthcare savings since 2015—and $56.2 billion in the past year—adoption remains uneven across therapeutic areas. A report highlights obstacles including pharmacy benefit managers (PBMs) favoring higher-priced brand drugs over cheaper biosimilars and a significant pipeline gap with only 12 biosimilars in development for 118 biologics losing patent protections by 2034. Stakeholders warn these factors could sustain high drug prices and limit patient access to affordable biologics.